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Abstract
Background: A stereoisomer of inositol, scyllo-inositol, is known as a promising therapeutic agent for Alzheimer’s
disease, since it prevents the accumulation of beta-amyloid deposits, a hallmark of the disease. However, this
compound is relatively rare in nature, whereas another stereoisomer of inositol, myo-inositol, is abundantly
available.
Results: Bacillus subtilis possesses a unique inositol metabolism involving both stereoisomers. We manipulated the
inositol metabolism in B. subtilis to permit the possible bioconversion from myo-inositol to scyllo-inositol. Within 48
h of cultivation, the engineered strain was able to convert almost half of 10 g/L myo-inositol to scyllo-inositol that
accumulated in the culture medium.
Conclusions: The engineered B. subtilis serves as a prototype of cell factory enabling a novel and inexpensive
supply of scyllo-inositol.
Background
Alzheimer’s disease is one of the most common and
problematic forms of dementia [1]. In 2006, 26.6 million
people suffered from Alzheimer’s disease worldwide, and
by 2050, the disease is predicted to increase, affecting 1
in every 85 individuals [2]. Hundreds of clinical trials
have been conducted to identify possible treatment stra-
tegies for the disease, but despite these efforts no pro-
mising strategy has been established. At present, most
of the treatment strategies currently used offer only a
small symptomatic benefit, and in fact no treatment is
available to stop the progression of the disease.
Inositol (1,2,3,4,5,6-cyclohexanehexol) has nine possi-
ble stereoisomers due to epimerization of the six hydro-
xyl groups. The most abundant stereoisomer in nature
is myo-inositol (compound 1, Figure 1), which is the
structural basis for a number of secondary messengers
in eukaryotic cells [3]. In plants, myo-inositol
hexakisphosphate or phytic a c i do f t e no c c u r si nh i g h
bran cereals, serving as the principal storage form of
phosphate. This is the main industrial source of myo-
inositol [4]. The other inositol stereoisomers are rela-
tively rare in nature but some exert specific health-pro-
moting activities. D-chiro-inositol (compound 2) is
beneficial for patients with hyperglycemia and polycystic
ovary syndrome since it restores insulin sensitivity [5]
and recovers normal ovulation [6], respectively. Accu-
mulating evidence indicates that another isomer, scyllo-
inositol (compound 3), has exceptional potential as a
therapeutic agent for Alzheimer’s disease [7].
scyllo-Inositol is sometimes found in plants and also
occurs naturally in human brain as a minor substance
that readily crosses the blood-brain barrier [8]. Aggrega-
tion of the beta-amyloid peptide in brain cells is a key
pathological feature of Alzheimer’s disease [9]. scyllo-
Inositol directly interacts with the beta-amyloid peptide
and blocks the development of fibers, alleviating mem-
ory deficits and other symptoms associated with beta-
amyloid accumulation [10,11]. Furthermore, mice fed
with scyllo-inositol have been demonstrated to have
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tion and greater longevity because the amyloid plaques
disappeared and inflammation declined. scyllo-Inositol
confers these benefits not only in very young disease-
free mice but also in diseased mice [7]. Thus, scyllo-ino-
sitol got fast-track designation from the US Food and
Drug Administration for treatment of mild to moderate
Alzheimer’s disease, and was granted a US patent in
2009 [12]. Phase 2 clinical trials of scyllo-inositol treat-
ment have already been conducted with positive results,
and plans for Phase 3 trials have been announced [13].
Bacillus subtilis is one of the best studied Gram-posi-
tive bacteria, and its unique inositol metabolism involves
at least three of the stereoisomers, myo-inositol, scyllo-
inositol, and D-chiro-inositol (Figure 1) [14]. The B. sub-
tilis iolABCDEFGHIJ operon encodes enzymes involved
in multiple steps of inositol metabolism [15]. In the first
step, myo-inositol is converted to scyllo-inosose (com-
pound 4, Figure 1) by myo-inositol dehydrogenase, IolG,
with NAD
+ reduction. IolG also dehydrogenates D-
chiro-inositol to 1-keto-D-chiro-inositol (compound 5),
which is subsequently isomerized by IolI to scyllo-ino-
sose [16]. In the second step, scyllo-inosose is dehy-
drated by IolE to 3D-(3,5/4)-trihydroxycyclohexane-1,2-
dione (compound 6) [17]. In the third step, IolD cata-
lyzes the hydrolysis of 3D-(3,5/4)-trihydroxycyclohex-
ane-1,2-dione to yield 5-deoxy-D-glucuronic acid
(compound 7). In the next step, IolB catalyzes the iso-
merization of 5-deoxy-D-glucuronic acid to 2-deoxy-5-
keto-D-gluconic acid (compound 8), which is subse-
quently phosphorylated by IolC kinase to 2-deoxy-5-
keto-D-gluconic acid 6-phosphate (compound 9) [18]. 2-
Deoxy-5-keto-D-gluconic acid 6-phosphate is an inter-
mediate that acts as an inducer by antagonizing DNA
binding of IoIR, a repressor controlling transcription of
the iol operon [19]. Finally, IolJ aldolase catalyzes the
conversion of 2-deoxy-5-keto-D-gluconic acid 6-phos-
phate to dihydroxyacetone phosphate (compound 10)
and malonic semialdehyde (compound 11). The former
is a glycolytic intermediate and the latter is converted to
acetyl-CoA (compound 12), which enters the tricar-
boxylic acid cycle, and CO2 by the IolA reaction.
B. subtilis possesses two additional and distinct inosi-
tol dehydrogenases, IolX and IolW, which specifically
act on scyllo-inositol with NAD
+ and NADP
+ reduction,
respectively [14]. Each of these enzymes convert scyllo-
inositol to scyllo-inosose, which is the same compound
produced from myo-inositol by IolG and is readily
degraded further via the metabolic pathway described
above [18]. iolX transcription is induced after the addi-
tion of scyllo-inositol to the growth medium of cells,
and its inactivation inhibits cell growth in the presence
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Figure 1 Inositol metabolism in B. subtilis. B. subtilis iol genes
encoding enzymes for reactions in the inositol catabolic pathway
and the respective intermediate compounds are shown. The
intermediate compounds are myo-inositol (compound 1), D-chiro-
inositol (compound 2), scyllo-inositol I (compound 3), scyllo-
inosose (compound 4), 1-keto-D-chiro-inositol (compound 5), 3D-
(3,5/4)-trihydroxycyclohexane-1,2-dione (compound 6), 5-deoxy-D-
glucuronic acid (compound 7), 2-deoxy-5-keto-D-gluconic acid
(compound 8), 2-deoxy-5-keto-D-gluconic acid 6-phosphate
(compound 9), dihydroxyacetone phosphate (compound 10),
malonic semialdehyde (compound 11), and acetyl-CoA
(compound 12).
Yamaoka et al. Microbial Cell Factories 2011, 10:69
http://www.microbialcellfactories.com/content/10/1/69
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could function physiologically as a catabolic enzyme
[14]. In contrast, iolW transcription is constitutive and
its inactivation does not alter the cell growth in the pre-
sence of scyllo-inositol. Our previous study suggested
that IolW may generate scyllo-inositol from scyllo-ino-
sose with NADPH oxidation, although its physiological
role remains unidentified [14].
In this study, we manipulated the inositol metabolism
in B. subtilis to control the interconversion among ino-
sitol stereoisomers secreted into the culture medium,
permitting a simple and inexpensive bioconversion of
myo-inositol to scyllo-inositol. The engineered B. subtilis
materialized our cell factory concept for scyllo-inositol
production.
Results and Discussion
Analyzing mutations for efficient bioconversion of myo-
inositol to scyllo-inositol
Previously we demonstrated that B. subtilis strain YF256
(Table 1) was capable of bioconverting myo-inositol to
D-chiro-inositol [16]. Because of iolR inactivation [19],
strain YF256 constitutively expresses iolG, iolE41,a n d
iolI. The missense mutation allele iolE41 abolishes IolE
dehydratase activity, resulting in the intracellular accu-
mulation of scyllo-inosose from myo-inositol due to the
IolG reaction [16]. scyllo-Inosose is isomerized by IolI to
1-keto-D-chiro-inositol and subsequently reduced by
IolG to D-chiro-inositol; thus, myo-inositol is converted
to D-chiro-inositol, which then appears in the inositol
bioconversion medium [16].
In this study, we re-examined the medium in which
strain YF256 was cultured for 24 h by an improved GC-
TOFMS system [20]. We were surprised to detect not
only D-chiro-inositol but also scyllo-inositol (Figure 2A),
thus revealing that our previous high-performance liquid
chromatography analysis failed to detect scyllo-inositol
[16]. Furthermore, this result suggested that some of the
accumulated scyllo-inosose could be converted to scyllo-
inositol, probably involving IolX and/or IolW.
When iolI was inactivated (strain TM038, Figure 2B),
conversion of scyllo-inosose to D-chiro-inositol
decreased to a negligible level, whereas that of scyllo-
inositol increased; however only slightly. These results
indicated that we could eliminate the metabolic pathway
for D-chiro-inositol by inactivating iolI, although this
was not sufficient to increase the conversion to scyllo-
inositol. Therefore, iolX and/or IolW were inactivated to
examine their involvement in scyllo-inositol production.
When iolW was functional, iolX inactivation alone dras-
tically elevated the concentration of scyllo-inositol pre-
sent in the medium (strain TM039, Figure 2C),
suggesting that IolX may degrade scyllo-inositol. In con-
trast, IolW was essential for efficient scyllo-inositol pro-
duction (strains TM040 and TM041, Figure 2D and 2E,
respectively). These results clearly indicate that IolW is
crucial for the conversion of scyllo-inosose to scyllo-
inositol.
Properties of the scyllo-inositol producing B. subtilis cell
factory
After 48-h culture of strain TM039 in the inositol bio-
conversion medium (Figure 3A), almost half of the myo-
inositol was converted to scyllo-inositol. This simple
bioconversion was so successful that it realized our con-
cept of cell factory to produce scyllo-inositol with higher
translational potential in the yield and purity of product
than the other methods previously described [21,22].
Further culture resulted in the consumption of not only
myo-inositol but also some of the scyllo-inositol, and
particularly myo-inositol was consumed almost comple-
tely after 96 h of culture whereas scyllo-inositol
remained relatively intact. The results implied that the
mutated IolE41 enzyme, which did not support cell
growth using myo-inositol as the carbon source [17],
might possibly retain a certain lower level of scyllo-ino-
sose degrading activity, which resulted in the decrease
in the two inositol isomers; because myo-inositol is pre-
ferentially converted to scyllo-inosose by IolG reaction,
it decreased more obviously. Although we do not have
Table 1 Bacterial strains used in this study.
Strain Relevant genotype Source or reference
60015 Wild-type Laboratory stock
BFS3018 iolX::pMutin2(erm) National Institute of Genetics [14]
FU341 asnH::spc [24]
TM038 iolE41 iolI::spc iolR::cat This work
TM039 iolE41 iolI::spc iolR::cat iolX::pMutin4(erm) This work
TM040 iolE41 iolI::spc iolR::cat iolW::pMutin2(erm::tet) This work
TM041 iolE41 iolI::spc iolR::cat iolW::pMutin2(erm::tet) iolX::pMutin4(erm) This work
TM043 iolW::pMutin2(erm::tet) [14]
YF256 iolE41 iolR::cat [17]
The integration vector pMutin2 originally possesses the erm marker [26], which was replaced with the tet marker in TM043 as described previously [23].
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tioned above, nevertheless the selective consumption of
myo-inositol could be even practical for a cell factory
making the scyllo-inositol product free from significant
myo-inositol contamination. However, to avoid wastage
of both the material and the product, possible strategies
to stop the inositol degradation will be considered,
including in-frame deletion of iolE.
In principal, we could assume that IolG reaction is
d u et oal o w e r i n go ft h ei n t r a c e l l u l a rN A D
+/NADH
ratio, whereas the IolW reaction elevates the NADP
+/ N A D P Hr a t i o( F i g u r e1 ) .I ft h i si sa c t u a l l yt h ec a s e ,
the inevitable problem of cofactor imbalance must have
been induced in the cells. Although considerably effi-
cient bioconversion has already been achieved (Figure
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Figure 2 Inositol stereoisomers present in the medium.S t r a i n s
of B. subtilis, including YF256 (A), TM038 (B), TM039 (C), TM040 (D),
or TM041 (E), were grown in the inositol bioconversion medium
containing 2% Bacto soytone. At the indicated time points, aliquots
of the culture medium were subjected to GC-TOFMS analysis as
described previously [20] in parallel with the initial medium (F) and
authentic standards as indicated (G). The experiments were
repeated independently at least three times with similar results, and
the representative data are shown.
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Figure 3 Time course of scyllo-inositol production and myo-
inositol consumption during inositol bioconversion along with
the cell growth. The bioconversion from myo-inositol to scyllo-
inositol was performed in the media containing 2% (A) or 1% (B)
Bacto soytone. The data presented are optical density of the cells
(black diamonds), and concentration of myo-inositol (black squares)
and scyllo-inositol (white triangles). The experiments were repeated
independently at least three times with similar results, and the
representative data sets are shown.
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cofactor imbalance under the given conditions. Interest-
ingly, when the major nutrient (Bacto soytone) con-
tained in the conversion medium was reduced by half,
no severe effect on the cell growth was observed, never-
theless only scyllo-inositol production was impaired sig-
nificantly while myo-inositol was consumed almost
completely (Figure 3B). The results imply that there
might be some nutritional and/or metabolic factors lim-
iting the bioconversion, which should be identified and
then controlled in the next generation of realistic cell
factory with optimized efficiency in scyllo-inositol
production.
It was demonstrated that B. subtilis possesses two dis-
tinct inositol transporters, IolT and IolF, which are dif-
ferent in substrate specificity to myo-inositol and D-
chiro-inositol [23]. Our preliminary observations sug-
gested that scyllo-inositol transport into the cells could
mainly depend on IolT, which is similar to myo-inositol
(data not shown), and overexpression of iolT may not
be effective for improving the conversion efficiency.
However, it has not yet been explained how the inositol
stereoisomers are secreted into the medium after con-
version; hence, we speculate the involvement of an
unknown efflux pump, which is also currently being
investigated as one of the possible targets to be
engineered.
Conclusions
B. subtilis is one of the best studied gram-positive bac-
teria. Its unique inositol metabolism has been comple-
tely elucidated to involve at least three inositol
stereoisomers, including scyllo-inositol and myo-inositol.
Our previous knowledge and findings suggested possible
interconversion among the stereoisomers. Therefore, we
manipulated the metabolic pathway to realize a cell fac-
tory concept enabling the simple and inexpensive bio-
conversion of myo-inositol to scyllo-inositol, which is a
promising therapeutic agent for Alzheimer’s disease.
Methods
Bacterial strains and their constructions
Bacterial strains used in this study are listed in Table 1.
The iolI gene of strain YF256 was inactivated by insert-
ing a spectinomycin resistance gene (spc) cassette as fol-
lows. A DNA fragment carrying the spc cassette was
amplified from strain FU341 DNA [24] by PCR using
IolI3F and IolI4R primer pair (Table 2). Further, two
DNA fragments corresponding to the upstream and
downstream regions of iolI were amplified from strain
60015 DNA by PCR using IolI1F/IolI2R and IolI5F/
Iol6R primer pairs, respectively, (Table 2). The 5’ end
sequences of IolI3F and Iol4R were complementary to
IolI2R and IolI5F, respectively. The three PCR fragments
were mixed and ligated using PCR performed with the
o u t s i d ep r i m e rp a i rI o l I F 1 / I o l 6 R .T h er e s u l t i n gP C R
fragment was used to transform strain YF256 to obtain
strain TM038 with spectinomycin resistance (iolI::spc;
Table 1).
Strain TM038 was transformed with strain BFS3018
D N A[ 1 4 ]t oo b t a i ns t r a i nT M 0 3 9w i t he r y t h r o m y c i n
resistance (iolX::pMutin4(erm); Table 1) and with
strain TM043 DNA [14] to obtain strain TM040 with
tetracycline resistance (iolW::pMutin2(erm::tet); Table
1). Strain TM040 was further transformed with strain
BFS3018 DNA to obtain strain TM041 with erythro-
mycin resistance (iolW::pMutin2(erm::tet) iolX::pMu-
tin4(erm); Table 1).
Culture conditions
Bacterial strains were maintained in Luria-Bertani med-
ium [25]. For inositol bioconversion, a 500-ml Sakaguchi
flask with a breathable foam stopper, containing 30 ml
of inositol bioconversion medium, containing 2% or 1%
(w/v) Bacto soytone (Becton, Dickinson and Co., Sparks,
MD), 0.5% Bacto yeast extract (Becton, Dickinson and
Co.), 0.5% NaCl, and 1% myo-inositol, was inoculated
with one of the B. subtilis strains at an optical density of
0.05 at 600 nm, and incubated at 37°C with shaking at
150 rpm.
Measurement of inositol stereoisomers in the medium
After bioconversion, aliquots of the culture medium
were subjected to gas chromatography-time-of-flight
mass spectrometry (GC-TOFMS) analysis as described
[20] but with some modifications as follows. After
removing bacterial cells by centrifugation, an aliquot of
the culture medium was evaporated in a test tube under
vacuum. The dried pellet was dissolved in the extraction
mixture of water, chloroform, and methanol (2:2:5), and
incubated at 150°C for 30 min with vigorous shaking.
After centrifugation at 40°C for 3 min at 16,000 g, the
supernatant was transferred to another tube and diluted
appropriately with pure water. After another centrifuga-
tion, part of the supernatant was dried completely in
another tube. The dried pellet was dissolved, and the
substances present in it were derivatized with methoxya-
mine hydrochloride in pyridine at 30°C for 90 min with
Table 2 Oligonucleotide primers used in this study
Primer Sequence
iolI1F 5’-TGCGGTTGAACTTGAAGTGG-3’
iolI2R 5’-TCTTCTGCTCTGTCACAAGC-3’
iolI3F 5’-GCTTGTGACAGAGCAGAAGACAATAACGCTATTGGGAG-3’
iolI4R 5’-GAACCCATTGCATGGAAGTGCTATATGCTCCTTCTGGC-3’
iolI5F 5’-CACTTCCATGCAATGGGTTC-3’
iolI6R 5’-ATATTGATCTTCGCGTGGCC-3’
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methylsilyl) trifluoroacetamide (GL Science, Tokyo,
Japan), the derivatized substances were further incu-
bated at 37°C for 30 min, and then injected via an Agi-
lent 7683B autosampler into an Agilent 7890A GC
(Agilent Technologies, Palo Alto, CA) coupled to a
Pegasus HT TOFMS (Leco Corp., St Joseph, MI) with
the settings as described [20]. Peak deconvolution iden-
tification and quantification were performed using the
Pegasus ChromaTOF software package ver. 4.21 (Leco
Corp.). Commercially available authentic inositols were
derivatized and analyzed in parallel with the experimen-
tal samples. The mass spectra and retention time
obtained were used to identify the stereoisomers, and
ion intensities were used to calculate concentration of
the stereoisomers.
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